24Jul
24Jul
L3 Networks Partners With Wasabi Technologies to Deliver Secure and Scalable Offsite Backup Storage Solutions
Bringing an extra measure of confidence to digital storage backup and restoration, from security to speed to scalability, managed service provider L3 Networks has finalized a partnership with Wasabi Technologies, the hot cloud storage company. This collaboration positions Wasabi as the company’s primary provider of offsite backup storage, enhancing the safety, efficiency, and dependability of L3’s data management services. Read more >>
20Jul
KnipBio Inc. welcomes new CEO
KnipBio, a leading precision fermentation biotechnology company, today announced new CEO, Caitlin Wege. The Board of Directors of KnipBio is pleased to announce the appointment of Caitlin Wege as its new Chief Executive Officer, effective immediately. Caitlin brings over 15 years of experience working with companies across various industries, with a sharp focus on operational excellence and strategic growth. She has a proven track record of leading organizational change that aligns with long-term goals. Read more >>
19Jul
Wasabi Technologies Now Available in Climb Channel Solutions’ Portfolio of GSA Offerings
Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) announced the expansion of their GSA IT-70 Contract (47QTCA19D008G) with the addition of Wasabi Technologies, a market leader in Hot Cloud Storage and strategic partner of Climb since 2020. As part of its GSA solutions, Climb will be offering Wasabi hot cloud storage, which delivers predictably priced, highly performant, and secure cloud object storage for customers that require an in-depth defense...
13Jul
D&D Pharmatech’s US unit to work with NIH, Johns Hopkins for Parkinson’s research
Neuraly, a U.S. subsidiary of D&D Pharmatech, has announced a collaboration with the National Institute on Aging (NIA) under the National Institutes of Health (NIH) and Johns Hopkins University School of Medicine to advance biomarker research using serum samples from patients involved in the phase 2 clinical trial of NLY01, a treatment for Parkinson's disease. NLY01, a long-acting GLP-1 receptor agonist, is being developed as a therapeutic for neurodegenerative diseases, including Parkinson's disease. he drug recently completed a global phase...
03Jul
Wasabi Technologies partners with Retelit to expand storage services in Italy
Cloud storage provider Wasabi Technologies has struck up a new partnership with technology infrastructure provider Retelit to expand cloud storages services in Italy. As part of the strategic partnership agreement, Retelit will sell Wasabi’s hot cloud storage as part of its core offering, while Wasabi will open the first Italian storage region in Milan. Scheduled to be operational in Q3 2024, the new region will be deployed in the newest hyper connected data center within Retelit’s Avalon Campus, Avalon 3,...
26Jun
EarthGrid Breaks Through on Major Milestones
EarthGrid Public Benefit Corporation (PBC), a plasma boring technology and development company, revealed today that their tunnel boring robot (TBR) has successfully completed several field tests at scale through some of the toughest tunneling geologies in the world. Additionally, the company is debuting its first-of-its-kind Plasma Excavation System (PES) featuring two plasma torches. These developments in tandem mark a significant step forward in the viability, efficiency and capabilities of the tunnel boring robot. This development announcement follows on the heels...
26Jun
Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity
Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today initiation of Phase 1b clinical study which is designed to provide proof-of-concept weight loss results, along with safety and tolerability, using an optimized formulation of the drug candidate XEN-101, in obese adults. The trial is expected to have top line results by the end of the year. The Phase 1b study is a double blinded, randomized, placebo...
18Jun
Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors
Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announced the appointment of Linda Rhodes, VMD, PhD to its Board of Directors. Dr. Rhodes brings Akston thirty years of experience in the animal health industry as a scientist, senior executive, and board member. Dr. Rhodes said, “I enjoy working with early-stage companies that have innovative solutions for animal health unmet needs. Akston combines a track record of inventing pioneering new therapies with the in-house capabilities critical...
15Jun